On June 1, 2022, TOT BIOPHARM (Stock code: 1875. HK) announced that the company entered into a Share Subscription Agreement…
Search Results: Tot Biopharm (96)
DMO Business Achieves Leapfrog Breakthrough Two Products Approved for Launch Smooth Progress of Various Core Anti-tumor Drugs Clinical Trials To…
Two Self-Developed Drugs Are Expected to be Approved for Marketing in 2021 TOT BIOPHARM International Company Limited (stock code: 1875.HK),…
Names Ms. Yeh-Huang, Chun-Ying as Vice Chairman of the Board Appoints Dr. Liu, Jun as Chief Executive Officer TOT BIOPHARM…
TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK) is pleased to announce that the randomized…
TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK), a clinical-stage biopharmaceutical company dedicated to developing…
On 6 March 2020, a morale-enhancing conference themed “Working Towards a World-class High-tech ePark & a New Summit for Reform…
Receives Central Government Funding TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK) is pleased to…
Granted Subsidy of RMB4 Million TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK) is pleased…
Suzhou-headquartered biotechnology firm Tot Biopharm has raised $102 million in Series B funding round backed by China Universal GP Ltd…
Innovative Products Continued to Deliver and Perform Excellently Revenue Recorded RMB26.20 Billion Adjusted non-HKFRS Profit Attributable to the Owners of…
Wuhan YZY Biopharma Co., Ltd. (YZY Biopharma or the Company, together with its subsidiaries, the Group, HKG: 2496), is officially…
Steadily Advances Innovation and R&D Revenue Climbs to RMB15.28 Billion Adjusted Non-HKFRS Profit Attributable to the Owners of the Parent…
Sihuan Pharmaceutical Holdings Group Ltd. (the Company or Sihuan Pharmaceutical, together with its subsidiaries, the Group, HKG: 0460) is pleased…
Revenue Up by 7.1% to RMB28.78 Billion Adjusted non-HKFRS Profit Attributable to the Owners of the Parent Up by 16.4%…
Benefitted from Years of Huge Investment in R&D Sales of New Products Accounts for 43.5% of Revenue Sino Biopharmaceutical Limited…
First Day Closed at HK$7.14, HK$0.01 Higher Than the Offer Price Representing an Increase of Approximately 0.14% The biopharmaceutical company…
Sirnaomics Ltd. (“Sirnaomics” or “Company”, together with its subsidiaries, the “Group”, stock code: 2257.HK), the RNA therapeutics biopharmaceutical company with…
K. Wah International Holdings Limited (KWIH or the Group) (HKG:173) today announced its unaudited interim results for the six months…
Contribution of Sales of New Products to Revenue Rises to 47.4% Driving Revenue Up by 16.4% Sino Biopharmaceutical Limited (Sino…